Cargando…
Brief Report: Rapid Clinical Recovery From Critical Coronavirus Disease 2019 With Respiratory Failure in a Pregnant Patient Treated With IV Vasoactive Intestinal Peptide
Aviptadil, a synthetic form of human vasoactive intestinal peptide, has entered clinical trials to treat critical coronavirus disease 2019 pneumonia with respiratory failure. Vasoactive intestinal peptide protects the lung against a broad array of injuries by binding to the vasoactive intestinal pep...
Autores principales: | Youssef, Jihad Georges, Bitar, Mohammad Z., Zahiruddin, Faisal, Al-Saadi, Mukhtar, Elshawwaf, Mahmoud, Yau, Simon, Goodarzi, Ahmad, Javitt, Jonathan C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8735760/ https://www.ncbi.nlm.nih.gov/pubmed/35018346 http://dx.doi.org/10.1097/CCE.0000000000000607 |
Ejemplares similares
-
Rapid Clinical Recovery from Critical COVID-19 Pneumonia with Vasoactive Intestinal Peptide Treatment
por: Beshay, S., et al.
Publicado: (2021) -
The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial*
por: Youssef, Jihad Georges, et al.
Publicado: (2022) -
Postulated Vasoactive Neuropeptide Autoimmunity in Fatigue-Related Conditions: A Brief Review and Hypothesis
por: Staines, Donald R.
Publicado: (2006) -
In vivo noninvasive systemic myography of acute systemic vasoactivity in female pregnant mice
por: Huda, Kristie, et al.
Publicado: (2023) -
A brief report on the effects of vasoactive agents on peripheral venous waveforms in a porcine model
por: Polcz, Monica, et al.
Publicado: (2020)